Saturday 17 October 2026
Export RNAC’s income statement to Excel — free account
Cartesian Therapeutics, Inc.
RNAC Healthcare Biotechnology
Cartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.9%, EPS fell 7.84% and free cash flow fell 6.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.27
0.31
−4.71%
Follow RNAC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 2 | 2 | — |
| 264.44% | 195.88% | 178.66% | 236.88% | ||
| (11.21%) | (35.63%) | (43.52%) | (42.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(31.81%) | (102.99%) | (128.92%) | (104.80%) | |
Average Days of Receivables |
241.55 | 145.50 | 53.67 | 0.00 | |
Free Cash Flow per Share |
(2.64) | (3.06) | (2.88) | (2.67) | |
Free Cash Flow |
(68.55) | (79.39) | (77.37) | (78.61) | |
Capital Expenditures |
(5.32) | (5.45) | (4.41) | (2.08) | |
| Other line items | |||||
Cash ROIC |
(63.74%) | 7,211.17% | 262.49% | (104.49%) | |
Accounts Receivable Turnover |
0.33 | 2.82 | 1.75 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,009.26% | 2,074.87% | 3,539.32% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,782.58% | 1,125.06% | 1,705.18% | 0.00% | |
Share Based Compensation of Revenue |
938.77% | 376.15% | 587.94% | 0.00% | |
Interest Coverage |
— | — | — | (54.00) | |
Operating CF/Net income |
1.36 | 0.57 | 0.48 | 0.51 | |
Depreciation/Fixed assets |
0.23 | 0.24 | 0.21 | 0.23 | |
Capex/Depreciation |
(1.87) | (1.84) | (1.82) | (0.80) | |
Revenue per Share |
0.04 | 0.11 | 0.07 | 0.00 | |
Operating CF per Share |
(2.43) | (2.85) | (2.72) | (2.60) | |
Capex per Share |
(0.20) | (0.21) | (0.16) | (0.07) | |
Capex to Sales |
4.87 | 1.95 | 2.48 | 0.00 |
Columns are period end dates